Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
TCR2 Therapeutics, a early stage biotech developing immunotherapies for various cancers, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. TCR2 Therapeutics plans to list on the Nasdaq under the symbol TCRR....read more
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
TCR2 Therapeutics, an early-stage biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: Blue jeans are back as Levi's preps March IPO
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Early stage cancer biotech TCR2 Therapeutics prices IPO at $15 midpoint
TCR2 Therapeutics, a early stage biotech developing immunotherapies for various cancers, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. TCR2 Therapeutics plans to list on the Nasdaq under the symbol TCRR....read more
US IPO Week Ahead: On track for 7 IPOs, led by Virgin Trains USA
Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six...read more
Immuno-oncology biotech TCR2 Therapeutics sets terms for $75 million IPO
TCR2 Therapeutics, an early-stage biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more